Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
21 participants
INTERVENTIONAL
2024-02-27
2024-10-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
To determine the feasibility of a patient self-management application (Urika) in patients with gout.
The intended purpose of the app is to support self-management for patients with gout that initiate urate lowering therapy.
"Urika", a self-management application for patients with gout
The self-management software application (Urika) will include information videos on gout and treatment, reminders of daily medication and blood tests, a built-in algorithm for medical dosage escalation, visualization and log of serum urate levels, motivational gamification, asynchronous chat function patient-health professionals, and a platform for remote monitoring by health professionals.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
"Urika", a self-management application for patients with gout
The self-management software application (Urika) will include information videos on gout and treatment, reminders of daily medication and blood tests, a built-in algorithm for medical dosage escalation, visualization and log of serum urate levels, motivational gamification, asynchronous chat function patient-health professionals, and a platform for remote monitoring by health professionals.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with a clinical diagnosis of gout
* Patients who fulfil the American College of Rheumatology (ACR)/EULAR classification criteria
* Serum urate level \>360 μmol/L at inclusion
* Having a smartphone/tablet
Exclusion Criteria
* Unstable medical conditions (e.g,, uncontrollable hypertension, impaired liver function); known stage 3b or higher chronic kidney disease (estimated glomerular filtration (eGFR) rate/creatinine clearance \<45 mL/min); severe infection or gastrointestinal bleed
* Major co-morbidities (e.g., malignancies, severe cardiovascular disease, severe diabetes mellitus, severe respiratory diseases)
* Psychiatric or mental disorders, alcohol abuse or other substance abuse, language barriers or other factors which makes adherence to the study protocol difficult
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Diakonhjemmet Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nina Osteras
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nina Østerås, Prof.
Role: PRINCIPAL_INVESTIGATOR
Diakonhjemmet Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Diakonhjemmet Hospital
Oslo, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023054
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
23/02662
Identifier Type: -
Identifier Source: org_study_id